Program 16th EU HIV & Hep (downloadable)

Session 4 - Clinical Management of PLWHXX


9:00Opening of the Meeting
9:15The role of the human microbiome on HIV infection
Roger Paredes, MD, PhD, Irsi Caixa Foundation, Barcelona, Spain
 Session 1 - The future of the HIV epidemic in Europe
9:45The HIV epidemic in CEE countries
Oana Sandulescu, MD, PhD, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
10:15HIV transmission in the migrant population
Dimitrios Paraskevis, PhD, National and Kapodistrian University of Athens Medical School, Athens, Greece
10:45How would the epidemic evolve in the future?
David van de Vijver, PharmD, PhD, Erasmus Medical Center, Rotterdam, the Netherlands
11:30Coffee break
 Special session - Improving Drug Delivery for Sustained Treatment Success
12:00Improving Drug Delivery: what are the new technologies?
Saye Khoo, MD, PhD, University of Liverpool, Liverpool, United Kingdom
12:20Long Acting HIV Drugs for Treatment: what are the data?
Anton Pozniak, MD, FRCP, Chelsea and Westminster Hospital, London, United Kingdom
12:40Long Acting HIV Drugs for Prevention: what are the data?
Pep Coll, MD, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
13:00Group picture
 Session 2 - Molecular epidemiology of HIV and Hepatitis
14:00A new wild-type in the era of transmitted drug resistance
Kristof Theys, PhD, University of Leuven, Belgium
14:30Abstract-driven presentations
15:15Coffee Break
 Session 3 - The roll-out of PrEP
15:45The current status of PrEP in Europe
Pep Coll, MD, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
16:15Influence of resistance in the future
Richard Harrigan, MD, PhD, BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
16:45Risk compensation in STDs
Jade Ghosn, MD, PhD, Hotel-Dieu University Hospital, Paris, France
17:30Guided poster tour 1: Epidemiology/transmission
18:00Welcome reception & poster viewing session 1

THURSDAY, MAY 31, 2018

 Session 4 - Abstract-driven presentations
8:30Abstract-driven presentations
09:30Guided poster tour 2: Clinical Management of PLWH
10:00Coffee break & poster viewing session 2
10:45Abstract-driven presentations
 Special session - Antiretroviral management: looking towards the horizon
11:30Clinical trial data 3 vs 2 drug regimens
Andrea de Luca, MD, University of Siena, Siena, Italy
11:45Longer term expectations around resistance
Carlo Perno, MD, PhD, University of Milan, Milan, Italy
12:00Implications for clinical practice
Jonathan Schapiro, MD, National Hemophilia Center, Tel Aviv, Israel
12:15Panel discussion
 Session 5 - Roundtable Discussion: Bringing the next generation sequencing to the clinic
13:30New technologies reaching the clinic
Martin Daeumer, MSc, Institute of Immunology and Genetics, Kaiserlautern, Germany


Novel simplified bioinformatics for NGS data analysis
Marc Noguera-Julian, PhD, irsiCaixa Foundation, Barcelona, Spain
14:30Roundtable discussion
15:00Coffee Break
 Session 6 - Management of Viral Hepatitis
15:30Management of Hepatitis C therapy failures - Virological perspective
Francesca Ceccherini - Silbersteini, PhD, University of Rome "Tor Vergata", Italy
16:00Management of Hepatitis C therapy failures - Clinical perspective
Sanjay Bhagani, BSc FRCP, Royal Free Hospital, London, United Kingdom
16:30Acute hepatitis A to E, Diagnosis and Management
Thomas Berg, MD, University Hospital Leipzig, Leipzig, Germany
17:00Abstract-driven presentations
18:00End of Program day 2
19:30Group dinner

FRIDAY, JUNE 1, 2018

 Session 7 - What's in the pipeline? Presentations by scientists from the industry 
8:30Romina Quercia, MD, PhD
ViiV Healthcare, United Kingdom
08:45Kathleen Squires, MD
Merck, USA
9:00Kirsten White, PhD
Gilead Sciences, USA
9:15Brinda Emu, MD
Theratechnologies / TaiMed Biologics, Yale School of Medicine, USA
9:30Jean-Marc Steens, MD
Abivax, France
10:15Guided poster tour 3: Hepatitis-related abstracts
10:45Coffee Break & Poster Viewing
 Session 8 - Novel therapeutic strategies & prospects for cure
11:15Reduced drug regimens
Andrea De Luca, MD, University of Siena, Italy
11:45What is the place of monoclonal antibodies in the clinic
Julià Blanco, PhD, IrsiCaixa Foundation, Barcelona, Spain
12:15Prospects for cure
Annemarie Wensing, MD, PhD, University Medical Center Utrecht, Utrecht, The Netherlands
13:00End of the meeting
 Invited Speakers